Female Genital Tract Cancers:@0.636526:0.035749:0.914557:0.035749:0.914557:0.019993:0.636526:0.019993:0.009333:0.012508:0.018049:0.013143:0.003848:0.012508:0.005330:0.016779:0.012508:0.011738:0.003848:0.006523:0.013143:0.003848:0.005330:0.007618:0.005792:0.013143:0.012450:0.006523:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
57:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
surgery followed by chemoradiation with :@0.084848:0.096166:0.481096:0.096166:0.481096:0.080410:0.084848:0.080410:0.007466:0.011699:0.005809:0.012950:0.012508:0.005792:0.010314:0.007757:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.007764:0.013123:0.010314:0.007774:0.012450:0.011738:0.012508:0.018049:0.012604:0.005792:0.013131:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.007764:0.015990:0.003848:0.006523:0.011738:0.005330
the use of cisplatin as a radiosensitiser. The :@0.084848:0.112464:0.481078:0.112464:0.481078:0.096708:0.084848:0.096708:0.006523:0.011738:0.012508:0.005138:0.011699:0.007466:0.012508:0.005138:0.012604:0.006042:0.005138:0.012450:0.003848:0.007466:0.013123:0.003860:0.013143:0.006523:0.003848:0.011738:0.005138:0.013143:0.007466:0.005138:0.013143:0.005138:0.005792:0.013143:0.013181:0.003848:0.012604:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.007466:0.012508:0.004385:0.005330:0.005138:0.008197:0.011738:0.012508:0.005330
treatment  of locally recurrent disease is :@0.084848:0.128762:0.481078:0.128762:0.481078:0.113006:0.084848:0.113006:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005244:0.012604:0.006042:0.010583:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.010583:0.005713:0.012508:0.012450:0.011699:0.005792:0.005703:0.012508:0.011738:0.006523:0.010583:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.010583:0.003848:0.007466:0.005330
surgery, if possible, or radiation if this has :@0.084848:0.145061:0.481063:0.145061:0.481063:0.129305:0.084848:0.129305:0.007466:0.011699:0.005809:0.012950:0.012508:0.005792:0.010314:0.005330:0.007966:0.003848:0.006042:0.007966:0.013123:0.012604:0.007466:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330:0.007982:0.012604:0.005792:0.007966:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.007966:0.003848:0.006042:0.007966:0.006523:0.011738:0.003848:0.007466:0.007966:0.011738:0.013143:0.007466:0.005330
not been given previously. For advanced :@0.084848:0.161359:0.481090:0.161359:0.481090:0.145603:0.084848:0.145603:0.011738:0.012604:0.006523:0.006716:0.013123:0.012508:0.012508:0.011738:0.006721:0.012950:0.003848:0.010660:0.012508:0.011738:0.006725:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330:0.006735:0.009333:0.012604:0.005792:0.006721:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330
or  recurrent disease, chemotherapy can :@0.084848:0.177657:0.481094:0.177657:0.481094:0.161901:0.084848:0.161901:0.012604:0.005792:0.005330:0.003319:0.005713:0.012508:0.012450:0.011699:0.005792:0.005707:0.012508:0.011738:0.006523:0.008659:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.008659:0.012450:0.011738:0.012508:0.018049:0.012604:0.006510:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.008659:0.012450:0.013143:0.011738:0.005330
be considered. Single agents such as plat-:@0.084848:0.193956:0.475777:0.193956:0.475777:0.178200:0.084848:0.178200:0.013123:0.012508:0.004830:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005715:0.012508:0.013181:0.005330:0.004830:0.009583:0.003848:0.011738:0.012950:0.003848:0.012508:0.004830:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.004830:0.007466:0.011699:0.012450:0.011738:0.004830:0.013143:0.007466:0.004830:0.013123:0.003848:0.013143:0.006523:0.006388
inum alone, paclitaxel  or topotecan all :@0.084848:0.210254:0.481084:0.210254:0.481084:0.194498:0.084848:0.194498:0.003848:0.011738:0.011699:0.018049:0.010853:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330:0.010853:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.005538:0.012604:0.005792:0.010853:0.006523:0.012604:0.013123:0.012604:0.006523:0.012508:0.012450:0.013143:0.011738:0.010853:0.013143:0.003848:0.003848:0.005330
have response rates. Combination chem-:@0.084848:0.226552:0.475773:0.226552:0.475773:0.210796:0.084848:0.210796:0.011738:0.013143:0.010660:0.012508:0.006254:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.006254:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.006242:0.015644:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.006244:0.012450:0.011738:0.012508:0.018049:0.006388
otherapy with platinum and paclitaxel has :@0.084848:0.242851:0.481080:0.242851:0.481080:0.227095:0.084848:0.227095:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004599:0.015990:0.003848:0.006523:0.011738:0.004599:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.004599:0.013143:0.011738:0.013181:0.004599:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.004610:0.011738:0.013143:0.007466:0.005330
been demonstrated with a modest sur-:@0.084848:0.259149:0.475796:0.259149:0.475796:0.243393:0.084848:0.243393:0.013123:0.012508:0.012508:0.011738:0.010987:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.010987:0.015990:0.003848:0.006523:0.011738:0.010987:0.013143:0.010987:0.018049:0.012604:0.013181:0.012508:0.007466:0.006523:0.010987:0.007466:0.011699:0.005792:0.006388
vival benefit of approximately two months :@0.084848:0.275447:0.481099:0.275447:0.481099:0.259691:0.084848:0.259691:0.010660:0.003848:0.010660:0.013143:0.003848:0.005201:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005174:0.012604:0.006042:0.005184:0.013143:0.013123:0.013123:0.005721:0.012604:0.009236:0.003848:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.005188:0.006523:0.015990:0.012604:0.005178:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330
with significant toxicity.:@0.084848:0.291746:0.297361:0.291746:0.297361:0.275990:0.084848:0.275990:0.015990:0.003848:0.006523:0.011738:0.005330:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330
16:@0.297351:0.286107:0.309781:0.286107:0.309781:0.276921:0.297351:0.276921:0.006215:0.006215
Adenocarcinoma of the cervix carries a :@0.103030:0.308023:0.481074:0.308023:0.481074:0.292267:0.103030:0.292267:0.014239:0.013181:0.012508:0.011738:0.012604:0.012450:0.013143:0.005646:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005465:0.012604:0.006042:0.005465:0.006523:0.011738:0.012508:0.005465:0.012450:0.012508:0.005792:0.010660:0.003848:0.009236:0.005465:0.012450:0.013143:0.005792:0.005792:0.003848:0.012508:0.007466:0.005465:0.013143:0.005330
very poor prognosis. Small-cell carcinoma :@0.084846:0.324321:0.481093:0.324321:0.481093:0.308565:0.084846:0.308565:0.010660:0.012508:0.005792:0.010314:0.006023:0.013123:0.012604:0.012604:0.005792:0.006009:0.013123:0.005715:0.012604:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.006023:0.009583:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.006023:0.012450:0.013143:0.005659:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330
should  be  treated  in  a  similar  manner  to :@0.084846:0.340619:0.481092:0.340619:0.481092:0.324863:0.084846:0.324863:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330:0.002931:0.013123:0.012508:0.005330:0.002933:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.002927:0.003848:0.011738:0.005330:0.002933:0.013143:0.005330:0.002934:0.007466:0.003848:0.018049:0.003848:0.003848:0.013158:0.005792:0.005330:0.002929:0.018049:0.013143:0.011738:0.011738:0.012508:0.005792:0.005330:0.002921:0.006523:0.012604:0.005330
small-cell carcinoma of the lung.:@0.084846:0.356918:0.389642:0.356918:0.389642:0.341162:0.084846:0.341162:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.012450:0.013143:0.005673:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.003848:0.011699:0.011738:0.012950:0.005330
ENDOMETRIAL CANCER:@0.084848:0.390153:0.345904:0.390153:0.345904:0.370556:0.084848:0.370556:0.012230:0.017404:0.016463:0.019756:0.021167:0.012230:0.009878:0.013641:0.006585:0.017404:0.010348:0.006585:0.018344:0.017404:0.017404:0.018344:0.012230:0.013641
The treatment recommendations for early- :@0.084848:0.408742:0.481099:0.408742:0.481099:0.392986:0.084848:0.392986:0.008197:0.011738:0.012508:0.004176:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004176:0.005711:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.004176:0.006042:0.012604:0.005792:0.004176:0.012508:0.013143:0.005792:0.003848:0.010314:0.006388:0.005330
stage disease, stages I to  III are primar-:@0.084848:0.425041:0.475783:0.425041:0.475783:0.409285:0.084848:0.409285:0.007466:0.006523:0.013143:0.012950:0.012508:0.009833:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.009833:0.007466:0.006523:0.013143:0.012950:0.012508:0.007466:0.009833:0.004349:0.009833:0.006523:0.012604:0.005330:0.004489:0.004349:0.004349:0.004349:0.009833:0.013143:0.005715:0.012508:0.009833:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.006388
ily surgery followed by radiation therapy. :@0.084848:0.441339:0.481103:0.441339:0.481103:0.425583:0.084848:0.425583:0.003848:0.003848:0.010314:0.008005:0.007466:0.011699:0.005807:0.012950:0.012508:0.005792:0.010314:0.008005:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.008005:0.013123:0.010314:0.008005:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.008005:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
The GOG 122 trial  compared whole ab-:@0.084848:0.457637:0.475764:0.457633:0.475764:0.441877:0.084848:0.441881:0.008197:0.011738:0.012508:0.006741:0.016779:0.016722:0.016779:0.006754:0.010660:0.010660:0.010660:0.006754:0.006523:0.005792:0.003848:0.013143:0.003848:0.012443:0.006754:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.006754:0.015990:0.011738:0.012604:0.003848:0.012508:0.006744:0.013143:0.013123:0.342440
17:@0.252964:0.452014:0.265394:0.452014:0.265394:0.442828:0.252964:0.442828:0.006215:0.006215
dominal radiotherapy to adjuvant chem-:@0.084847:0.473931:0.475766:0.473931:0.475766:0.458175:0.084847:0.458175:0.013181:0.012604:0.018049:0.003848:0.011738:0.013143:0.003848:0.007139:0.005792:0.013143:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007139:0.006523:0.012604:0.007129:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.007139:0.012450:0.011738:0.012508:0.018049:0.006388
otherapy in patients with stages III to IVa :@0.084847:0.490229:0.481071:0.490229:0.481071:0.474473:0.084847:0.474473:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007909:0.003848:0.011738:0.007909:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007909:0.015990:0.003848:0.006523:0.011738:0.007909:0.007466:0.006523:0.013143:0.012950:0.012508:0.007466:0.007909:0.004349:0.004349:0.004349:0.007909:0.006523:0.012604:0.007909:0.004349:0.011511:0.013143:0.005330
disease. There was both a progression-free :@0.084847:0.506528:0.481106:0.506528:0.481106:0.490772:0.084847:0.490772:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.004445:0.008197:0.011738:0.012508:0.005703:0.012508:0.004435:0.015990:0.013143:0.007466:0.004445:0.013123:0.012604:0.006523:0.011738:0.004430:0.013143:0.004445:0.013123:0.005715:0.012604:0.012950:0.005713:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005715:0.012508:0.012508:0.005330
as well as an overall survival benefit that :@0.084847:0.522826:0.481092:0.522826:0.481092:0.507070:0.084847:0.507070:0.013143:0.007466:0.007916:0.015990:0.012508:0.003848:0.003848:0.007918:0.013143:0.007466:0.007916:0.013143:0.011738:0.007911:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.007914:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.007926:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.007903:0.006523:0.011738:0.013143:0.006523:0.005330
favoured the chemotherapy arm of dox-:@0.084847:0.539124:0.475772:0.539124:0.475772:0.523368:0.084847:0.523368:0.006042:0.013143:0.010660:0.012604:0.011699:0.005711:0.012508:0.013181:0.007312:0.006523:0.011738:0.012508:0.007312:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007299:0.013143:0.006325:0.018049:0.007312:0.012604:0.006042:0.007312:0.013181:0.012604:0.009236:0.006388
orubicin and cisplatin.  This form of adju-:@0.084847:0.555423:0.475760:0.555423:0.475760:0.539667:0.084847:0.539667:0.012604:0.005792:0.011699:0.013123:0.003848:0.012450:0.003848:0.011738:0.009198:0.013143:0.011738:0.013181:0.009198:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.005330:0.003879:0.008197:0.011738:0.003848:0.007466:0.009198:0.006042:0.012604:0.006323:0.018049:0.009198:0.012604:0.006042:0.009198:0.013143:0.013181:0.003906:0.011699:0.006388
vant chemotherapy has not been widely :@0.084847:0.571721:0.481085:0.571721:0.481085:0.555965:0.084847:0.555965:0.010660:0.013143:0.011738:0.006523:0.007120:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007108:0.011738:0.013143:0.007466:0.007120:0.011738:0.012604:0.006523:0.007110:0.013123:0.012508:0.012508:0.011738:0.007120:0.015990:0.003848:0.013181:0.012508:0.003848:0.010314:0.005330
used because the control arm in the study :@0.084847:0.588019:0.481098:0.588019:0.481098:0.572263:0.084847:0.572263:0.011699:0.007466:0.012508:0.013181:0.004839:0.013123:0.012508:0.012450:0.013143:0.011699:0.007466:0.012508:0.004849:0.006523:0.011738:0.012508:0.004832:0.012450:0.012604:0.011738:0.006523:0.005702:0.012604:0.003848:0.004839:0.013143:0.006325:0.018049:0.004838:0.003848:0.011738:0.004849:0.006523:0.011738:0.012508:0.004832:0.007466:0.006523:0.011699:0.013181:0.010314:0.005330
was not  considered  a standard  of  care. :@0.084847:0.604318:0.481104:0.604318:0.481104:0.588562:0.084847:0.588562:0.015990:0.013143:0.007466:0.008890:0.011738:0.012604:0.006523:0.005330:0.003546:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005709:0.012508:0.013181:0.005330:0.003548:0.013143:0.008890:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005675:0.013181:0.005330:0.003550:0.012604:0.006042:0.005330:0.003544:0.012450:0.013143:0.005713:0.012508:0.005330:0.005330
Chemotherapy used as a single agent or :@0.084847:0.620616:0.481079:0.620616:0.481079:0.604860:0.084847:0.604860:0.015644:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.006831:0.011699:0.007466:0.012508:0.013181:0.006831:0.013143:0.007466:0.006843:0.013143:0.006831:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.006831:0.013143:0.012950:0.012508:0.011738:0.006523:0.006831:0.012604:0.005792:0.005330
in combination has been studied in stage :@0.084847:0.636914:0.481067:0.636914:0.481067:0.621158:0.084847:0.621158:0.003848:0.011738:0.006138:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.006138:0.011738:0.013143:0.007466:0.006138:0.013123:0.012508:0.012508:0.011738:0.006138:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.013181:0.006138:0.003848:0.011738:0.006138:0.007466:0.006523:0.013143:0.012950:0.012508:0.005330
IV disease. :@0.084847:0.653213:0.188814:0.653213:0.188814:0.637457:0.084847:0.637457:0.004349:0.013508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005330
Randomised trials including doxorubicin :@0.103031:0.669511:0.481086:0.669511:0.481086:0.653755:0.103031:0.653755:0.011680:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.006427:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.006427:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.006427:0.013181:0.012604:0.009236:0.012604:0.005792:0.011699:0.013123:0.003848:0.012450:0.003848:0.011738:0.005330
alone  or  in combination  have failed to :@0.084847:0.685809:0.481111:0.685809:0.481111:0.670053:0.084847:0.670053:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330:0.005282:0.012604:0.005792:0.005330:0.005278:0.003848:0.011738:0.010622:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005282:0.011738:0.013143:0.010660:0.012508:0.010622:0.006042:0.013143:0.003848:0.003848:0.012508:0.013181:0.010622:0.006523:0.012604:0.005330
show a survival advantage. The GOG 177 :@0.084847:0.702108:0.481061:0.702108:0.481061:0.686352:0.084847:0.686352:0.007466:0.011738:0.012604:0.015990:0.005965:0.013143:0.005965:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003862:0.005965:0.013143:0.013181:0.010660:0.013143:0.011738:0.006523:0.013143:0.012950:0.012508:0.005330:0.005965:0.008197:0.011738:0.012508:0.005965:0.016779:0.016722:0.016779:0.005965:0.010660:0.010660:0.010660:0.005330
trial   compared  platinum plus paclitaxel :@0.084847:0.718406:0.481095:0.718380:0.481095:0.702624:0.084847:0.702650:0.006523:0.005792:0.003848:0.013143:0.003848:0.012439:0.005330:0.003356:0.012450:0.012604:0.018049:0.013123:0.013143:0.005717:0.012508:0.013181:0.005330:0.003358:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.008698:0.013123:0.003848:0.011699:0.007466:0.008698:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:-0.043217
18:@0.118006:0.712761:0.130436:0.712761:0.130436:0.703575:0.118006:0.703575:0.006215:0.006215
to  the  same combination together  with :@0.084855:0.734678:0.481104:0.734678:0.481104:0.718922:0.084855:0.718922:0.006523:0.012604:0.005330:0.004857:0.006523:0.011738:0.012508:0.005330:0.004859:0.007466:0.013143:0.018049:0.012508:0.010198:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.010198:0.006523:0.012604:0.012950:0.012508:0.006523:0.011738:0.012508:0.005792:0.005330:0.004841:0.015990:0.003848:0.006523:0.011738:0.005330
doxorubicin (TAP). A progression-free and :@0.084855:0.750976:0.481095:0.750976:0.481095:0.735220:0.084855:0.735220:0.013181:0.012604:0.009236:0.012604:0.005792:0.011699:0.013123:0.003848:0.012450:0.003848:0.011738:0.006948:0.007100:0.006637:0.014239:0.011392:0.007100:0.005330:0.006952:0.014239:0.006950:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005711:0.012508:0.012508:0.006950:0.013143:0.011738:0.013181:0.005330
an overall survival benefit were seen, but :@0.084855:0.767275:0.481100:0.767275:0.481100:0.751519:0.084855:0.751519:0.013143:0.011738:0.007187:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.007197:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.007201:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.007177:0.015990:0.012508:0.005713:0.012508:0.007185:0.007466:0.012508:0.012508:0.011738:0.005330:0.007183:0.013123:0.011699:0.006523:0.005330
at  the  expense  of  considerable toxicity, :@0.084855:0.783573:0.481110:0.783573:0.481110:0.767817:0.084855:0.767817:0.013143:0.006523:0.005330:0.004643:0.006523:0.011738:0.012508:0.005330:0.004639:0.012508:0.009236:0.013123:0.012508:0.011738:0.007466:0.012508:0.005330:0.004641:0.012604:0.006042:0.005330:0.004641:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.009987:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330:0.005330
including grade 3 symptomatic heart fail-:@0.084855:0.799871:0.475759:0.799871:0.475759:0.784115:0.084855:0.784115:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.006465:0.012950:0.005792:0.013143:0.013181:0.012508:0.006456:0.010660:0.006465:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.013143:0.006523:0.003848:0.012450:0.006465:0.011738:0.012508:0.013143:0.005792:0.006523:0.006450:0.006042:0.013143:0.003848:0.003848:0.006388
ure. Granulocyte colony-stimulating fac-:@0.084855:0.816170:0.475761:0.816170:0.475761:0.800414:0.084855:0.800414:0.011699:0.005711:0.012508:0.005330:0.010218:0.016779:0.005792:0.013143:0.011738:0.011699:0.003848:0.012604:0.012450:0.010314:0.006523:0.012508:0.010218:0.012450:0.012604:0.003848:0.012604:0.011738:0.010314:0.006388:0.007466:0.006523:0.003848:0.018049:0.011699:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.010218:0.006042:0.013143:0.012450:0.006388
tor (G-CSF) was required.:@0.084855:0.832468:0.317909:0.832468:0.317909:0.816712:0.084855:0.816712:0.006523:0.012604:0.005792:0.005330:0.007100:0.016779:0.006388:0.015644:0.009583:0.009333:0.007100:0.005330:0.015990:0.013143:0.007466:0.005330:0.005705:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.013181:0.005330
REFERENCES:@0.084855:0.862128:0.195691:0.862128:0.195691:0.846094:0.084855:0.846094:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.084848:0.878965:0.103800:0.878965:0.103800:0.864960:0.084848:0.864960:0.009476:0.004738:0.004738
 Hess  V,:@0.121195:0.878965:0.180369:0.878965:0.180369:0.864960:0.121195:0.864960:0.000000:0.011682:0.011118:0.006636:0.006636:0.004738:0.003429:0.010196:0.004738
 et al.:@0.180369:0.878965:0.233444:0.878965:0.233444:0.864960:0.180369:0.864960:0.008159:0.011118:0.005798:0.008159:0.011682:0.003421:0.004738
  Mucinous epithelial  ovarian :@0.233444:0.878965:0.480500:0.878965:0.480500:0.864960:0.233444:0.864960:0.004738:0.003428:0.015719:0.010399:0.011067:0.003421:0.010434:0.011203:0.010399:0.006636:0.008159:0.011118:0.011665:0.003421:0.005798:0.010434:0.011118:0.003421:0.003421:0.011682:0.003421:0.004738:0.003431:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.004738
cancer: a separate entity requiring specific :@0.121195:0.893206:0.480493:0.893206:0.480493:0.879200:0.121195:0.879200:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004302:0.011682:0.004312:0.006636:0.011118:0.011665:0.011682:0.005148:0.011682:0.005798:0.011118:0.004310:0.011118:0.010434:0.005798:0.003421:0.005798:0.009168:0.004307:0.005078:0.011118:0.011665:0.010399:0.003421:0.005148:0.003421:0.010434:0.011511:0.004309:0.006636:0.011665:0.011118:0.011067:0.003421:0.004165:0.004165:0.011067:0.004738
treatment. :@0.121195:0.907446:0.213524:0.907446:0.213524:0.893441:0.121195:0.893441:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004726:0.004738
J Clin Oncol:@0.213524:0.907446:0.313414:0.907446:0.313414:0.893441:0.213524:0.893441:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421
. 2004;22:1040-1044.:@0.313414:0.907446:0.475443:0.907446:0.475443:0.893441:0.313414:0.893441:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
2. :@0.084848:0.921686:0.103800:0.921686:0.103800:0.907681:0.084848:0.907681:0.009476:0.004738:0.004738
 Lee YY,:@0.121195:0.921686:0.179276:0.921686:0.179276:0.907681:0.121195:0.907681:0.000000:0.007902:0.011118:0.011118:0.004623:0.010126:0.008456:0.004738
 et al.:@0.179276:0.921686:0.225294:0.921686:0.225294:0.907681:0.179276:0.907681:0.004635:0.011118:0.005798:0.004625:0.011682:0.003421:0.004738
 Prognosis of ovarian clear cell :@0.225294:0.921686:0.480508:0.921686:0.480508:0.907681:0.225294:0.907681:0.004635:0.010126:0.005075:0.011203:0.011511:0.010434:0.011203:0.006636:0.003421:0.006636:0.004627:0.011203:0.005371:0.004623:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.004635:0.011067:0.003421:0.011118:0.011682:0.005148:0.004627:0.011067:0.011118:0.003421:0.003421:0.004738
carcinoma compared to other histological :@0.121195:0.935927:0.480494:0.935927:0.480494:0.921922:0.121195:0.921922:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004863:0.011067:0.011203:0.016044:0.011665:0.011682:0.005080:0.011118:0.011716:0.004863:0.005798:0.011203:0.004859:0.011203:0.005798:0.010434:0.011118:0.005148:0.004851:0.010434:0.003421:0.006636:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.011682:0.003421:0.004738
subtypes: a meta-analysis:@0.560589:0.094752:0.779952:0.094752:0.779952:0.080747:0.560589:0.080747:0.006636:0.010399:0.011665:0.005798:0.009168:0.011665:0.011118:0.006636:0.004738:0.008227:0.011682:0.008227:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636
. Gynaecol On-:@0.779970:0.094752:0.915145:0.094752:0.915145:0.080747:0.779970:0.080747:0.004738:0.008227:0.014915:0.009168:0.010434:0.011682:0.011118:0.011067:0.011203:0.003421:0.008227:0.014864:0.010434:0.005679
col:@0.560589:0.109063:0.586280:0.109063:0.586280:0.095058:0.560589:0.095058:0.011067:0.011203:0.003421
. 2011;122:541-547.:@0.586280:0.109063:0.738834:0.109063:0.738834:0.095058:0.586280:0.095058:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
3. :@0.524242:0.123374:0.543194:0.123374:0.543194:0.109369:0.524242:0.109369:0.009476:0.004738:0.004738
  Vergote I,:@0.560589:0.123374:0.642440:0.123374:0.642440:0.109369:0.560589:0.109369:0.004738:-0.004738:0.010281:0.011118:0.005159:0.011511:0.011203:0.005798:0.011118:0.007059:0.003866:0.004738
 et al.:@0.642440:0.123374:0.693326:0.123374:0.693326:0.109369:0.642440:0.109369:0.007064:0.011118:0.005798:0.007064:0.011682:0.003421:0.004738
 Prognostic importance of :@0.693326:0.123374:0.919883:0.123374:0.919883:0.109369:0.693326:0.109369:0.007064:0.010126:0.005073:0.011203:0.011511:0.010434:0.011203:0.006636:0.005798:0.003421:0.011067:0.007064:0.003421:0.016044:0.011665:0.011203:0.005148:0.005798:0.011682:0.010434:0.011067:0.011118:0.007064:0.011203:0.005371:0.004738
degree of differentiation and cyst rupture :@0.560589:0.137685:0.919902:0.137685:0.919902:0.123680:0.560589:0.123680:0.011716:0.011118:0.011511:0.005075:0.011118:0.011118:0.006961:0.011203:0.005371:0.006961:0.011716:0.003421:0.005426:0.005371:0.011118:0.005075:0.011118:0.010434:0.005798:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.006961:0.011682:0.010434:0.011716:0.006961:0.011067:0.009168:0.006636:0.005798:0.006961:0.005148:0.010399:0.011665:0.005798:0.010399:0.005071:0.011118:0.004738
in stage I invasive epithelial ovarian carci-:@0.560589:0.151996:0.915152:0.151996:0.915152:0.137991:0.560589:0.137991:0.003421:0.010434:0.006320:0.006636:0.005798:0.011682:0.011511:0.011118:0.006315:0.003866:0.006329:0.003421:0.010434:0.009476:0.011682:0.006636:0.003421:0.009491:0.011118:0.006317:0.011118:0.011665:0.003421:0.005798:0.010434:0.011118:0.003421:0.003421:0.011682:0.003421:0.006329:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.006320:0.011067:0.011682:0.005029:0.011067:0.003421:0.005679
noma. :@0.560589:0.166307:0.619428:0.166307:0.619428:0.152302:0.560589:0.152302:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
Lancet. :@0.619411:0.166307:0.686888:0.166307:0.686888:0.152302:0.619411:0.152302:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738:0.004738
2001;357:1761-82.:@0.686870:0.166307:0.829948:0.166307:0.829948:0.152302:0.686870:0.152302:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
4. :@0.524225:0.180618:0.543177:0.180618:0.543177:0.166613:0.524225:0.166613:0.009476:0.004738:0.004738
  Bell  J,:@0.560572:0.180618:0.609278:0.180618:0.609278:0.166613:0.560572:0.166613:0.004738:-0.004738:0.009818:0.011118:0.003421:0.003421:0.004738:0.003209:0.008244:0.004738
 et al.:@0.609278:0.180618:0.661908:0.180618:0.661908:0.166613:0.609278:0.166613:0.007936:0.011118:0.005798:0.007936:0.011682:0.003421:0.004738
 Randomised phase III trial of :@0.661908:0.180618:0.919859:0.180618:0.919859:0.166613:0.661908:0.166613:0.007936:0.010382:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.007936:0.011665:0.010434:0.011682:0.006636:0.011118:0.007936:0.003866:0.003866:0.003866:0.007936:0.005798:0.005148:0.003421:0.011682:0.003421:0.007936:0.011203:0.005371:0.004738
three:@0.560572:0.194929:0.604113:0.194929:0.604113:0.180924:0.560572:0.180924:0.005798:0.010434:0.005073:0.011118:0.011118
 versus:@0.604113:0.194929:0.660728:0.194929:0.660728:0.180924:0.604113:0.180924:0.007201:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636
 six cycles of adjuvant carbo-:@0.660728:0.194929:0.915147:0.194929:0.915147:0.180924:0.660728:0.180924:0.007201:0.006636:0.003421:0.008210:0.007201:0.011067:0.009168:0.011067:0.003421:0.011118:0.006636:0.007201:0.011203:0.005371:0.007192:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.007201:0.011067:0.011682:0.005148:0.011665:0.011203:0.005679
platin and paclitaxel in early stage  epi-:@0.560572:0.209240:0.915152:0.209240:0.915152:0.195235:0.560572:0.195235:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.009972:0.011682:0.010434:0.011716:0.009972:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.009972:0.003421:0.010434:0.009972:0.011118:0.011682:0.005148:0.003421:0.009168:0.009972:0.006636:0.005798:0.011682:0.011511:0.011118:0.004738:0.005224:0.011118:0.011665:0.003421:0.005679
thelial ovarian carcinoma: a Gynecologic :@0.560572:0.223845:0.919871:0.223845:0.919871:0.209840:0.560572:0.209840:0.005798:0.010434:0.011118:0.003421:0.003421:0.011682:0.003421:0.006414:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.006414:0.011067:0.011682:0.005027:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.006404:0.011682:0.006414:0.014915:0.009168:0.010434:0.011118:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.004738
Oncology  Group  study. :@0.560572:0.238450:0.771361:0.238450:0.771361:0.224445:0.560572:0.224445:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.005990:0.014915:0.005080:0.011203:0.010399:0.011665:0.004738:0.005995:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Gynecol Oncol:@0.777365:0.238450:0.910419:0.238450:0.910419:0.224445:0.777365:0.224445:0.014915:0.009168:0.010434:0.011118:0.011067:0.011203:0.003421:0.010742:0.014864:0.010434:0.011067:0.011203:0.003421
. :@0.910419:0.238450:0.919895:0.238450:0.919895:0.224445:0.910419:0.224445:0.004738:0.004738
2006;102:432-439.:@0.560572:0.253055:0.703650:0.253055:0.703650:0.239050:0.560572:0.239050:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
5. :@0.524225:0.267660:0.543177:0.267660:0.543177:0.253655:0.524225:0.253655:0.009476:0.004738:0.004738
  Polterauer S,:@0.560572:0.267660:0.665887:0.267660:0.665887:0.253655:0.560572:0.253655:0.004738:-0.004738:0.010126:0.011203:0.003421:0.005798:0.011118:0.005148:0.011682:0.010399:0.011118:0.005148:0.006896:0.008518:0.004738
 et al.:@0.665887:0.267660:0.716464:0.267660:0.716464:0.253655:0.665887:0.253655:0.006910:0.011118:0.005798:0.006910:0.011682:0.003421:0.004738
 Prognostic value of re-:@0.716464:0.267660:0.915116:0.267660:0.915116:0.253655:0.716464:0.253655:0.006910:0.010126:0.005075:0.011203:0.011511:0.010434:0.011203:0.006636:0.005798:0.003412:0.011067:0.006910:0.009476:0.011682:0.003421:0.010399:0.011118:0.006910:0.011203:0.005371:0.006910:0.005078:0.011118:0.005679
sidual tumor size in patients with epithelial :@0.560572:0.282265:0.919847:0.282265:0.919847:0.268260:0.560572:0.268260:0.006636:0.003421:0.011716:0.010399:0.011682:0.003421:0.006755:0.005798:0.010399:0.016044:0.011203:0.005148:0.006739:0.006636:0.003421:0.007269:0.011118:0.006739:0.003421:0.010434:0.006739:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.006739:0.014214:0.003421:0.005798:0.010434:0.006739:0.011118:0.011665:0.003421:0.005798:0.010434:0.011118:0.003421:0.003421:0.011682:0.003421:0.004738
ovarian cancer FIGO stages IIA-IV: analysis :@0.560572:0.296870:0.919852:0.296870:0.919852:0.282865:0.560572:0.282865:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.005183:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005183:0.008296:0.003866:0.014915:0.014864:0.005183:0.006636:0.005798:0.011682:0.011511:0.011118:0.006636:0.005183:0.003866:0.003866:0.012657:0.005679:0.003866:0.011994:0.004738:0.005183:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738
of the OVCAD data. :@0.560572:0.311475:0.734352:0.311475:0.734352:0.297470:0.560572:0.297470:0.011203:0.005371:0.004447:0.005798:0.010434:0.011118:0.004447:0.014864:0.012007:0.013906:0.012657:0.012726:0.004447:0.011716:0.011682:0.005798:0.011682:0.004738:0.004738
Int J Gynecol Cancer:@0.734061:0.311475:0.910424:0.311475:0.910424:0.297470:0.734061:0.297470:0.003866:0.010434:0.005798:0.004447:0.008244:0.004447:0.014915:0.009168:0.010434:0.011118:0.011067:0.011203:0.003421:0.004447:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148
. :@0.910424:0.311475:0.919900:0.311475:0.919900:0.297470:0.910424:0.297470:0.004738:0.004738
2012;22:380-385.:@0.560572:0.326080:0.694174:0.326080:0.694174:0.312075:0.560572:0.312075:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
6. :@0.524225:0.340685:0.543177:0.340685:0.543177:0.326680:0.524225:0.326680:0.009479:0.004734:0.004738
  Du Bois A,:@0.560572:0.340685:0.639423:0.340685:0.639423:0.326680:0.560572:0.326680:0.004738:-0.004738:0.012384:0.010057:0.004823:0.009476:0.010861:0.003079:0.006294:0.004823:0.012315:0.004738
 et al.:@0.639081:0.340685:0.684117:0.340685:0.684117:0.326680:0.639081:0.326680:0.004823:0.010776:0.005456:0.004823:0.011340:0.003079:0.004738
 A randomised clinical trial of :@0.683775:0.340685:0.919832:0.340685:0.919832:0.326680:0.683775:0.326680:0.004823:0.012315:0.004823:0.004806:0.011340:0.010092:0.011374:0.010861:0.015702:0.003079:0.006294:0.010776:0.011374:0.004823:0.010724:0.003079:0.003079:0.010092:0.003079:0.010724:0.011340:0.003079:0.004823:0.005456:0.004806:0.003079:0.011340:0.003079:0.004823:0.010861:0.005371:0.004738
cisplatin/paclitaxel:@0.560572:0.355290:0.710577:0.355290:0.710577:0.341285:0.560572:0.341285:0.010724:0.003079:0.006294:0.011323:0.003079:0.011340:0.005456:0.003079:0.010092:0.007133:0.011323:0.011340:0.010724:0.003079:0.003079:0.005456:0.011340:0.007868:0.010776:0.003421
 versus:@0.710235:0.355290:0.763806:0.355290:0.763806:0.341285:0.710235:0.341285:0.005867:0.009134:0.010776:0.004806:0.006294:0.010057:0.006636
 carboplatin/pacli-:@0.763464:0.355290:0.915103:0.355290:0.915103:0.341285:0.763464:0.341285:0.005858:0.010724:0.011340:0.004806:0.011323:0.010861:0.011323:0.003079:0.011340:0.005456:0.003079:0.010092:0.007133:0.011323:0.011340:0.010724:0.003079:0.003079:0.005679
taxel as first-line treatment of ovarian cancer:@0.560572:0.369895:0.910758:0.369895:0.910758:0.355890:0.560572:0.355890:0.005456:0.011340:0.007868:0.010776:0.003079:0.003665:0.011340:0.006294:0.003664:0.003994:0.003994:0.004806:0.006294:0.005456:0.005337:0.003079:0.003079:0.010092:0.010776:0.003665:0.005456:0.004734:0.010776:0.011340:0.005456:0.015702:0.010776:0.010092:0.005456:0.003665:0.010861:0.005029:0.003665:0.010861:0.009134:0.011340:0.004806:0.003079:0.011340:0.010092:0.003665:0.010724:0.011340:0.010092:0.010724:0.010776:0.005148
. :@0.910416:0.369895:0.919892:0.369895:0.919892:0.355890:0.910416:0.355890:0.004738:0.004738
J Natl Cancer Inst:@0.560572:0.384500:0.700862:0.384500:0.700862:0.370495:0.560572:0.370495:0.007902:0.004396:0.012315:0.011340:0.005456:0.003079:0.004396:0.013564:0.011340:0.010092:0.010724:0.010776:0.004806:0.004396:0.003523:0.010092:0.006294:0.005798
. 2003;95:1320-1329.:@0.700520:0.384500:0.856050:0.384500:0.856050:0.370495:0.700520:0.370495:0.004396:0.004396:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.009134:0.004738
7. :@0.524225:0.399105:0.543177:0.399105:0.543177:0.385100:0.524225:0.385100:0.009476:0.004738:0.004738
  Vergote I,:@0.560572:0.399105:0.638954:0.399105:0.638954:0.385100:0.560572:0.385100:0.004738:-0.004738:0.010281:0.011118:0.005159:0.011511:0.011203:0.005798:0.011118:0.003590:0.003866:0.004738
 et al.:@0.638954:0.399105:0.682907:0.399105:0.682907:0.385100:0.638954:0.385100:0.003600:0.011118:0.005798:0.003595:0.011682:0.003421:0.004738
 Neo-adjuvant chemothera-:@0.682907:0.399105:0.915128:0.399105:0.915128:0.385100:0.682907:0.385100:0.003600:0.012657:0.011118:0.011203:0.005679:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.003595:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011665:0.005679
py or primary surgery in stage IIIC or IV ovar-:@0.560572:0.413710:0.915168:0.413710:0.915168:0.399705:0.560572:0.399705:0.011665:0.009168:0.003831:0.011203:0.005148:0.003831:0.011665:0.005148:0.003421:0.016044:0.011682:0.005148:0.009168:0.003831:0.006636:0.010399:0.005162:0.011511:0.011118:0.005148:0.009168:0.003823:0.003421:0.010434:0.003831:0.006636:0.005798:0.011682:0.011511:0.011118:0.003831:0.003866:0.003866:0.003866:0.013906:0.003831:0.011203:0.005148:0.003831:0.003866:0.012007:0.003831:0.011203:0.009476:0.011682:0.005148:0.005679
ian cancer. :@0.560572:0.428315:0.658708:0.428315:0.658708:0.414310:0.560572:0.414310:0.003421:0.011682:0.010434:0.003866:0.011067:0.011682:0.010434:0.011067:0.011118:0.003891:0.004738:0.004738
N Engl J Med:@0.657836:0.428315:0.763421:0.428315:0.763421:0.414310:0.657836:0.414310:0.012657:0.003866:0.009168:0.010434:0.011511:0.003421:0.003866:0.008244:0.003866:0.015719:0.011118:0.011716
. 2012;363:943-953.:@0.763421:0.428315:0.915125:0.428315:0.915125:0.414310:0.763421:0.414310:0.004738:0.003866:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009498:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
8. :@0.524225:0.442920:0.543177:0.442920:0.543177:0.428915:0.524225:0.428915:0.009476:0.004738:0.004738
  Armstrong  DK,:@0.560572:0.442920:0.684421:0.442920:0.684421:0.428915:0.560572:0.428915:0.004738:-0.004738:0.012657:0.005617:0.016044:0.006636:0.005798:0.005078:0.011203:0.010434:0.011511:0.004738:0.006560:0.012726:0.010109:0.004738
 et al.:@0.684421:0.442920:0.743790:0.442920:0.743790:0.428915:0.684421:0.428915:0.011306:0.011118:0.005798:0.011306:0.011682:0.003421:0.004738
 Intraperitoneal cis-:@0.743790:0.442920:0.915142:0.442920:0.915142:0.428915:0.743790:0.428915:0.011306:0.003866:0.010434:0.005798:0.005148:0.011682:0.011665:0.011118:0.005148:0.003421:0.005798:0.011203:0.010434:0.011118:0.011682:0.003421:0.011306:0.011067:0.003421:0.006636:0.005679
platin and paclitaxel  in ovarian cancer.  :@0.560572:0.457525:0.919866:0.457525:0.919866:0.443520:0.560572:0.443520:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.010382:0.011682:0.010434:0.011716:0.010382:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.004738:0.005655:0.003421:0.010434:0.010382:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.010382:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.000000:0.004738
N Engl J Med:@0.560572:0.472718:0.668774:0.472718:0.668774:0.458713:0.560572:0.458713:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716
. 2006;354:34-43.:@0.668757:0.472718:0.802359:0.472718:0.802359:0.458713:0.668757:0.458713:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
9. :@0.524225:0.487911:0.543177:0.487911:0.543177:0.473906:0.524225:0.473906:0.009476:0.004738:0.004738
  Ozols RF,:@0.560572:0.487911:0.631324:0.487911:0.631324:0.473906:0.560572:0.473906:0.004738:-0.004738:0.014864:0.007269:0.011203:0.003421:0.006636:0.006034:0.010382:0.006204:0.004738
 et al.:@0.631324:0.487911:0.680147:0.487911:0.680147:0.473906:0.631324:0.473906:0.006038:0.011118:0.005798:0.006028:0.011682:0.003421:0.004738
 Phase III trial of carboplatin :@0.680147:0.487911:0.919880:0.487911:0.919880:0.473906:0.680147:0.473906:0.006038:0.010126:0.010434:0.011682:0.006636:0.011118:0.006029:0.003866:0.003866:0.003866:0.006038:0.005798:0.005148:0.003421:0.011682:0.003421:0.006038:0.011203:0.005371:0.006028:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738
and paclitaxel compared with cisplatin :@0.560572:0.503104:0.919846:0.503104:0.919846:0.489099:0.560572:0.489099:0.011682:0.010434:0.011716:0.012059:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.012059:0.011067:0.011203:0.016044:0.011665:0.011682:0.005077:0.011118:0.011716:0.012059:0.014214:0.003421:0.005798:0.010434:0.012059:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738
and paclitaxel in patients with optimally re-:@0.560572:0.518297:0.915144:0.518297:0.915144:0.504292:0.560572:0.504292:0.011682:0.010434:0.011716:0.004541:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.004550:0.003421:0.010434:0.004550:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004550:0.014214:0.003421:0.005798:0.010434:0.004541:0.011203:0.011665:0.005798:0.003421:0.016044:0.011682:0.003421:0.003421:0.009168:0.004550:0.005078:0.011118:0.005679
sected stage III ovarian cancer: a gyneco-:@0.560572:0.533490:0.915128:0.533490:0.915128:0.519485:0.560572:0.519485:0.006636:0.011118:0.011067:0.005798:0.011118:0.011716:0.004772:0.006636:0.005798:0.011682:0.011511:0.011118:0.004772:0.003866:0.003866:0.003866:0.004772:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.004772:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004760:0.011682:0.004772:0.011511:0.009168:0.010434:0.011118:0.011067:0.011181:0.005679
logic oncology group study:@0.560572:0.548683:0.794607:0.548683:0.794607:0.534677:0.560572:0.534677:0.003421:0.011203:0.011511:0.003421:0.011067:0.006876:0.011203:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.006876:0.011511:0.005077:0.011203:0.010399:0.011665:0.006876:0.006636:0.005798:0.010399:0.011716:0.009168
. J Clin Oncol.:@0.794607:0.548683:0.915125:0.548683:0.915125:0.534677:0.794607:0.534677:0.004738:0.006876:0.008244:0.006876:0.013906:0.003421:0.003421:0.010434:0.006876:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 :@0.915125:0.548683:0.919863:0.548683:0.919863:0.534677:0.915125:0.534677:0.004738
2003;21:3194-3200.:@0.560572:0.563876:0.713126:0.563876:0.713126:0.549870:0.560572:0.549870:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
10.   Vasey  PA,:@0.524225:0.579069:0.643165:0.579069:0.643165:0.565063:0.524225:0.565063:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010230:0.011682:0.006636:0.011118:0.009168:0.004738:0.002773:0.008853:0.012657:0.004738
 et al.:@0.643165:0.579069:0.694940:0.579069:0.694940:0.565063:0.643165:0.565063:0.007509:0.011118:0.005798:0.007509:0.011682:0.003421:0.004738
 Phase III randomised trial :@0.694940:0.579069:0.919897:0.579069:0.919897:0.565063:0.694940:0.565063:0.007509:0.010126:0.010434:0.011682:0.006636:0.011118:0.007509:0.003866:0.003866:0.003866:0.007509:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.007509:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738
of docetaxel-carboplatin:@0.560572:0.594262:0.769741:0.594262:0.769741:0.580256:0.560572:0.580256:0.011203:0.005371:0.004396:0.011716:0.011203:0.011067:0.011118:0.005798:0.011682:0.008210:0.011118:0.003421:0.005679:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434
 versus:@0.769741:0.594262:0.823551:0.594262:0.823551:0.580256:0.769741:0.580256:0.004396:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636
 paclitaxel-:@0.823551:0.594262:0.915111:0.594262:0.915111:0.580256:0.823551:0.580256:0.004396:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.005679
carboplatin  as  first-line  chemotherapy  for :@0.560572:0.609455:0.919881:0.609455:0.919881:0.595449:0.560572:0.595449:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738:0.003385:0.011682:0.006636:0.004738:0.003388:0.004165:0.004165:0.005148:0.006636:0.005798:0.005679:0.003421:0.003421:0.010434:0.011118:0.004738:0.003383:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010420:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.003385:0.005371:0.011203:0.005148:0.004738
ovarian  carcinoma.:@0.560572:0.624648:0.731692:0.624648:0.731692:0.610642:0.560572:0.610642:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.004738:0.006970:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738
  J Natl  Cancer  Inst.:@0.731692:0.624648:0.915137:0.624648:0.915137:0.610642:0.731692:0.610642:0.004738:0.006968:0.008244:0.011701:0.012657:0.011682:0.005798:0.003421:0.004738:0.006968:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.006963:0.003866:0.010434:0.006636:0.005798:0.004738
 :@0.751643:0.624648:0.756381:0.624648:0.756381:0.610642:0.751643:0.610642:0.004738
 :@0.915137:0.624648:0.919875:0.624648:0.919875:0.610642:0.915137:0.610642:0.004738
2004;96:1682-1691.:@0.560572:0.639841:0.713126:0.639841:0.713126:0.625835:0.560572:0.625835:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
11.   International Collaborative Ovarian  Neo-:@0.524225:0.655033:0.915128:0.655033:0.915128:0.641028:0.524225:0.641028:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.003866:0.010434:0.005798:0.011118:0.005499:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.009749:0.013906:0.011203:0.003421:0.003421:0.011682:0.011665:0.011203:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.009749:0.014864:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.004738:0.005024:0.012657:0.011118:0.011200:0.005679
plasm  Group. Paclitaxel plus carboplatin:@0.560572:0.670226:0.915121:0.670226:0.915121:0.656221:0.560572:0.656221:0.011665:0.003421:0.011682:0.006636:0.016044:0.004738:0.004733:0.014915:0.005078:0.011203:0.010399:0.011665:0.004738:0.009459:0.010126:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.009459:0.011665:0.003421:0.010399:0.006636:0.009459:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434
 :@0.915121:0.670226:0.919859:0.670226:0.919859:0.656221:0.915121:0.656221:0.004738
versus:@0.560572:0.685419:0.609986:0.685419:0.609986:0.671414:0.560572:0.671414:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636
 standard chemotherapy with either :@0.609986:0.685419:0.919880:0.685419:0.919880:0.671414:0.609986:0.671414:0.006166:0.006636:0.005798:0.011682:0.010434:0.011716:0.011682:0.005044:0.011716:0.006175:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006156:0.014214:0.003421:0.005798:0.010434:0.006166:0.011118:0.003421:0.005798:0.010434:0.011118:0.005148:0.004738
single-agent  carboplatin or  cyclophos-:@0.560572:0.700612:0.915138:0.700612:0.915138:0.686607:0.560572:0.686607:0.006636:0.003421:0.010434:0.011511:0.003421:0.011118:0.005679:0.011682:0.011511:0.011118:0.010434:0.005798:0.004738:0.010834:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.015582:0.011203:0.005148:0.004738:0.010830:0.011067:0.009168:0.011067:0.003421:0.011203:0.011665:0.010434:0.011203:0.006636:0.005679
phamide, doxorubicin, and cisplatin in :@0.560572:0.715805:0.919883:0.715805:0.919883:0.701800:0.560572:0.701800:0.011665:0.010434:0.011682:0.016044:0.003421:0.011716:0.011118:0.004738:0.013974:0.011716:0.011203:0.008210:0.011203:0.005148:0.010399:0.011665:0.003421:0.011067:0.003421:0.010434:0.004738:0.013974:0.011682:0.010434:0.011716:0.013974:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.013974:0.003421:0.010434:0.004738
women  with ovarian cancer:  the ICON3 :@0.560572:0.730998:0.919880:0.730998:0.919880:0.716993:0.560572:0.716993:0.014214:0.011203:0.016044:0.011118:0.010434:0.004738:0.004712:0.014214:0.003421:0.005798:0.010434:0.009459:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.009459:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.004709:0.005798:0.010434:0.011118:0.009459:0.003866:0.013906:0.014864:0.012657:0.009476:0.004738
randomised trial. :@0.560572:0.746191:0.703376:0.746191:0.703376:0.732186:0.560572:0.732186:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.004738:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Lancet:@0.703376:0.746191:0.761377:0.746191:0.761377:0.732186:0.703376:0.732186:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798
. 202;360:505-515.:@0.761377:0.746191:0.904455:0.746191:0.904455:0.732186:0.761377:0.732186:0.004738:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
12.   Perren TJ,:@0.524225:0.761384:0.640530:0.761384:0.640530:0.747379:0.524225:0.747379:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.011118:0.005148:0.005068:0.011118:0.010434:0.006678:0.007286:0.008244:0.004738
 et al.:@0.640530:0.761384:0.690663:0.761384:0.690663:0.747379:0.640530:0.747379:0.006688:0.011118:0.005798:0.006688:0.011682:0.003421:0.004738
 A Phase III trial of bevaci-:@0.690663:0.761384:0.915161:0.761384:0.915161:0.747379:0.690663:0.747379:0.006688:0.012657:0.006678:0.010126:0.010434:0.011682:0.006636:0.011118:0.006678:0.003866:0.003866:0.003866:0.006688:0.005798:0.005148:0.003421:0.011682:0.003421:0.006688:0.011203:0.005371:0.006678:0.011665:0.011118:0.009476:0.011682:0.011067:0.003421:0.005679
zumab  in ovarian cancer. :@0.560572:0.776577:0.788089:0.776577:0.788089:0.762572:0.560572:0.762572:0.007269:0.010399:0.016044:0.011682:0.011665:0.004738:0.003530:0.003421:0.010434:0.008279:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.008279:0.011067:0.011682:0.010434:0.011067:0.011118:0.003888:0.004738:0.004738
N  Engl  J  Med:@0.791600:0.776577:0.910395:0.776577:0.910395:0.762572:0.791600:0.762572:0.012657:0.004738:0.003529:0.009168:0.010434:0.011511:0.003421:0.004738:0.003532:0.008244:0.004738:0.003532:0.015719:0.011118:0.011716
. :@0.910395:0.776577:0.919871:0.776577:0.919871:0.762572:0.910395:0.762572:0.004738:0.004738
2011;365:2484-2496.:@0.560572:0.791770:0.722601:0.791770:0.722601:0.777765:0.560572:0.777765:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
13.   Aghajanian  C,:@0.524225:0.806375:0.682406:0.806375:0.682406:0.792370:0.524225:0.792370:0.009479:0.009479:0.004731:0.004738:0.007914:0.000000:0.012486:0.011340:0.010263:0.011511:0.003301:0.011511:0.010263:0.003250:0.011511:0.010263:0.004738:0.002930:0.013735:0.004738
 et al.:@0.682235:0.806375:0.733634:0.806375:0.733634:0.792370:0.682235:0.792370:0.007663:0.010947:0.005627:0.007663:0.011511:0.003250:0.004738
 OCEANS: A random- :@0.733463:0.806375:0.919866:0.806375:0.919866:0.792370:0.733463:0.792370:0.007663:0.014693:0.013735:0.008997:0.012486:0.012486:0.008347:0.004567:0.007663:0.012486:0.007663:0.004977:0.011511:0.010263:0.011545:0.011032:0.015873:0.005679:0.004738
ised, double-blind, placebo-controlled phase  :@0.560572:0.820980:0.919866:0.820980:0.919866:0.806975:0.560572:0.806975:0.003079:0.006294:0.010776:0.011374:0.004396:0.001950:0.011374:0.010861:0.010057:0.011323:0.003079:0.010776:0.005337:0.011323:0.003079:0.003079:0.010092:0.011374:0.004396:0.001950:0.011323:0.003079:0.011340:0.010724:0.010776:0.011323:0.010861:0.005337:0.010724:0.010861:0.010092:0.005456:0.004734:0.010861:0.003079:0.003079:0.010776:0.011374:0.001950:0.011498:0.010259:0.011513:0.006469:0.011116:0.000000:0.004738
III trial of chemotherapy with or without :@0.560572:0.835585:0.919883:0.835585:0.919883:0.821580:0.560572:0.821580:0.003866:0.003866:0.003866:0.010092:0.005798:0.005148:0.003421:0.011682:0.003421:0.010092:0.011203:0.005371:0.010092:0.011067:0.010434:0.011118:0.016044:0.011220:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.010092:0.014214:0.003421:0.005798:0.010434:0.010092:0.011203:0.005148:0.010092:0.014214:0.003421:0.005798:0.010434:0.011203:0.010399:0.005798:0.004738
bevacizumab in patients with platinum-:@0.560572:0.849896:0.915128:0.849896:0.915128:0.835891:0.560572:0.835891:0.011665:0.011118:0.009476:0.011682:0.011067:0.003421:0.007269:0.010399:0.016044:0.011682:0.011665:0.011563:0.003421:0.010434:0.011563:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.011563:0.014214:0.003421:0.005798:0.010434:0.011563:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.010399:0.016044:0.005679
sensitive recurrent epithelial ovarian, pri-:@0.560572:0.864207:0.915133:0.864207:0.915133:0.850202:0.560572:0.850202:0.006636:0.011118:0.010434:0.006636:0.003421:0.005798:0.003421:0.009476:0.011118:0.010519:0.005078:0.011118:0.011067:0.010399:0.005148:0.005070:0.011118:0.010434:0.005798:0.010519:0.011118:0.011665:0.003421:0.005798:0.010434:0.011118:0.003421:0.003421:0.011682:0.003421:0.010519:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.004738:0.010519:0.011665:0.005148:0.003421:0.005679
mary peritoneal, or fallopian tube cancer:@0.560572:0.878518:0.910421:0.878518:0.910421:0.864513:0.560572:0.864513:0.016044:0.011682:0.005148:0.009168:0.005987:0.011665:0.011118:0.005148:0.003421:0.005798:0.011203:0.010434:0.011118:0.011682:0.003421:0.004738:0.005987:0.011203:0.005148:0.005975:0.005371:0.011682:0.003421:0.003421:0.011203:0.011665:0.003421:0.011682:0.010434:0.005987:0.005798:0.010399:0.011665:0.011118:0.005978:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148
. :@0.910421:0.878518:0.919897:0.878518:0.919897:0.864513:0.910421:0.864513:0.004738:0.004738
J Clin Oncol:@0.560572:0.892829:0.660461:0.892829:0.660461:0.878824:0.560572:0.878824:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421
. 1201;30:2039-2045.:@0.660461:0.892829:0.822491:0.892829:0.822491:0.878824:0.660461:0.878824:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
14.   Pujade-Lauraine  E,:@0.524225:0.907140:0.719827:0.907140:0.719827:0.893135:0.524225:0.893135:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.010399:0.003472:0.011682:0.011716:0.011118:0.005679:0.007902:0.011682:0.010399:0.005148:0.011682:0.003421:0.010434:0.011118:0.004738:0.004632:0.009168:0.004738
 et al.:@0.719827:0.907140:0.775331:0.907140:0.775331:0.893135:0.719827:0.893135:0.009373:0.011118:0.005798:0.009373:0.011682:0.003421:0.004738
  Pegylated lipo-:@0.775331:0.907140:0.915128:0.907140:0.915128:0.893135:0.775331:0.893135:0.004738:0.004639:0.010126:0.011118:0.011511:0.009168:0.003421:0.011682:0.005798:0.011118:0.011716:0.009373:0.003421:0.003421:0.011665:0.011203:0.005679
somal doxorubicin and carboplatin  com-:@0.560572:0.921451:0.915154:0.921451:0.915154:0.907446:0.560572:0.907446:0.006636:0.011203:0.016044:0.011682:0.003421:0.008176:0.011716:0.011203:0.008210:0.011203:0.005148:0.010399:0.011665:0.003421:0.011067:0.003421:0.010434:0.008176:0.011682:0.010434:0.011716:0.008176:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738:0.003429:0.011067:0.011203:0.016044:0.005679
pared with paclitaxel and carboplatin :@0.560572:0.935762:0.919868:0.935762:0.919868:0.921757:0.560572:0.921757:0.011665:0.011682:0.005082:0.011118:0.011716:0.014231:0.014214:0.003421:0.005798:0.010434:0.014231:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.014231:0.011682:0.010434:0.011716:0.014231:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738